SEC Form 4 · accession 0000899243-16-017254
PROVECTUS BIOPHARMACEUTICALS, INC. · PVCT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jan Koe
Director
Period of report
Mar 29, 2016
Accepted (ET)
Mar 31, 2016 · 7:31 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000315545
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 29, 2016 | O | 100,000 | $1.25 | A | 686,300 | D | |
| Common StockF1 | Mar 29, 2016 | O | 100,000 | $1.25 | A | 786,300 | D | |
| Common Stock | holding | — | — | — | 150,000 | I | By Vekoe Partners LLC |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock Warrants (right to buy)F1 | $1.25 | Mar 29, 2016 | O | 100,000 | D | Jun 28, 2012 | Apr 15, 2016 | Common Stock | 100,000 | 0 | D |
| Common Stock Warrants (right to buy)F1 | $0.85 | Mar 29, 2016 | O | 100,000 | A | Mar 29, 2016 | Jun 19, 2020 | Common Stock | 100,000 | 100,000 | D |
| Common Stock Warrants (right to buy)F1 | $1.25 | Mar 29, 2016 | O | 100,000 | D | Apr 20, 2011 | Apr 20, 2016 | Common Stock | 100,000 | 0 | D |
| Common Stock Warrants (right to buy)F1 | $0.85 | Mar 29, 2016 | O | 100,000 | A | Mar 29, 2016 | Jun 19, 2020 | Common Stock | 100,000 | 100,000 | D |
Explanation of responses
- F1On March 29, 2016, the reporting person exercised an aggregate of 200,000 warrants pursuant to the Issuer's warrant exchange offer, at a discounted exercise price of $0.50 per share, which exercise consisted of: (i) an exercise of 100,000 shares pursuant to a warrant issued on June 28, 2012, with an original exercise price of $1.25 per share and (ii) an exercise of 100,000 shares pursuant to a warrant issued on September 20, 2013, with an original exercise price of $1.25 per share. Under the terms of the warrant exchange offer, holders received, in addition to the common stock acquired upon exercise of their existing warrants, an equal number of new warrants to purchase the same number of shares of the Issuer's common stock at an exercise price of $0.85 per share that will expire June 19, 2020.